Syndrome News and Research

RSS

Study explores the prevalence of long COVID in England

A review of long COVID studies conducted in March 2021 summarized the available literature on the persistent symptoms after acute COVID-19. The review also reported that most studies included hospitalized patients who had a higher prevalence of persistent symptoms compared to two community-based studies.

7 Jul 2021

Real-world evidence for effectiveness of vaccination against 4 SARS-CoV-2 VOCs in Canada

Toronto-based researchers recently conducted a study to determine the effectiveness of BNT162b2 (Pfizer-BioNTech), mRNA-1273 (Moderna), and ChAdOx1 (AstraZeneca) vaccines against symptomatic COVID-19 infection caused by the Alpha, Beta, Gamma, and Delta variants between December 2020 to May 2021.

7 Jul 2021

Vaccinate big cats? New report shows SARS-CoV-2 Delta variant infecting endangered lions

There is evidence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infecting animals such as ferrets, fruit bats, and cats. New research led by Vijendra Pal Singh from the ICAR-National Institute of High Security Animal Disease in India suggests it might be time to vaccinate the big cats as well. Their report details SARS-CoV-2 infection in nine Asiatic lions caused by the SARS-CoV-2 Delta variant (B.1.617.2).

7 Jul 2021

SARS-CoV-2 Lambda variant spreading rapidly in South America, report reveals

A new research paper by researchers in Peru describes a new variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) known as the Lambda variant (C.37). The Lambda variant was first reported in Lima, Peru, in December 2020, and from April 2021, nearly all the coronavirus infections in the country are caused by it.

7 Jul 2021

Study shows antibody titers after natural SARS-CoV-2 infection last longer than previously thought

A recent study by researchers from the United Kingdom (UK) revealed that antibody levels associated with protection against reinfection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are likely to last from 1.5 to 2 years on average and that the protection from severe infection may be present for several years.

7 Jul 2021

COVID-19 vaccination may be stemming evolution of “fitter” SARS-CoV-2 variants

Researchers in the United States and India have presented the first known evidence that the rollout of coronavirus disease 2019 (COVID-19) vaccination is restricting the evolutionary and immune escape pathways accessible to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

6 Jul 2021

Moderna’s COVID-19 vaccine elicits durable T cell memory and antibody responses

Researchers in the United States have shown that Moderna’s mRNA-1273 coronavirus disease 2019 (COVID-19) vaccine induces durable antibody and T cell responses to the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that are comparable to those seen in cases of COVID-19 caused by natural SARS-CoV-2 infection.

6 Jul 2021

Fecal transplant and fiber supplementation can benefit patients with obesity-related metabolic syndrome

A transplant of healthy gut microbes followed by fiber supplements benefits patients with severe obesity and metabolic syndrome, according to University of Alberta clinical trial findings published today in Nature Medicine.

6 Jul 2021

22 blood plasma lipids found to be associated with lower symptom improvement in schizophrenia

Researchers from Skoltech and the Mental Health Research Center have found 22 lipids in the blood plasma of people with schizophrenia that were associated with lower symptom improvement over time during treatment.

6 Jul 2021

Plant compounds inhibit Mpro of SARS-CoV-2 and HCoV-229E in vitro

A group of researchers recently discussed their findings that a group of plant flavonols and dihydroflavonols exhibit antiviral efficacy against both SARS-CoV-2 and HCoV-229E.

6 Jul 2021

Deletion of an embryonic gene in liver cells completely wipes out bile ducts of newborn mice

Scientists from the University of Pittsburgh School of Medicine described a new phenomenon in which the deletion of a single gene involved in liver embryogenesis completely wipes out bile ducts of newborn mice.

6 Jul 2021

Study provides a reliable early prognostic biomarker for COVID-19 severity

In a retrospective, multi-centre cohort study conducted by researchers from Nanjing University, Huazhong University of Science and Technology, Jinling Hospital and the Second Hospital of Nanjing, a microRNA-like small RNA encoded by SARS-CoV-2 was identified in the serum of COVID-19 patients, which can be developed as a non-invasive biomarker for stratification of severe patients from mild/moderate ones and for identification of high-risk individuals before clinical manifestation of severe symptoms.

6 Jul 2021

Angiotensin II type 1 receptor-targeting autoantibodies may increase COVID-19 severity

A team of US-based scientists recently demonstrated that pro-thrombotic autoantibodies that target angiotensin II type 1 receptor (AT1R) may be associated with endothelial complications observed in coronavirus disease 2019 (COVID-19), a novel disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

6 Jul 2021

Serum testosterone status recovery an accurate predictor of survival in male COVID-19 patients

In a study available on the medRxiv* the preprint server, researchers from Spain showed that testosterone trajectories are very accurate individual predictors of survival in male patients with COVID-19. To better understand the relationship between testosterone levels and disease severity, they studied a group of male and female COVID-19 patients assessing their serum and blood biomarkers in association with outcome of disease.

6 Jul 2021

Study examines evolution and avidity of anti-SARS-CoV-2 IgG antibodies after mRNA vaccination

New research released on the medRxiv* preprint server has measured antibody responses in 71 mRNA vaccinated adults (54 vaccinated with Pfizer and 17 vaccinated with Moderna).

6 Jul 2021

Study explores the effects of SARS-CoV-2 (and other betacoronaviruses) on cellular mRNA processing

A new study has been released on the bioRxiv* preprint server, which deals with a comprehensive survey on alternative splicing concerning SARS-CoV-2 infection. This study has also included two other betacoronavirurses (SARS-CoV and MERS), a control set of unrelated viruses, and a bacterium, namely, Streptococcus pneumonia. The study findings suggest that several cellular parameters are affected owing to a betacoronavirus infection, which in turn affects some genes and invariably various biological functions.

6 Jul 2021

COVID-19 recovered vaccinated individuals more protected from Delta variant

The B.1.617 lineage of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), first detected in October 2020, has led to new outbreaks of the infection and new waves of the pandemic. This infectious lineage has resulted in the generation of sub-lineages such as B.1.617.1 (Kappa), B.1.617.2 (Delta) and B.1.617.3.

6 Jul 2021

CRISPRa identifies potassium channels as neuronal entry factors and druggable targets for SARS-CoV-2

New research led by Le Cong of Stanford University School of Medicine in California indicates that the KCNA6 potassium channel may help with viral entry and promote infection. In addition, KCNA6 is highly expressed in OLIG2+ neuronal cells, which has been shown to be suspectable to SARS-CoV-2 in the olfactory neuroepithelium. This area appears to contribute to loss of smell commonly observed during infection.

6 Jul 2021

Study explores how human ACE2 variants can modify SARS-CoV-2 binding

A recent tour-de-force study by researchers from the United Kingdom reveals variants of the human angiotensin-converting enzyme 2 (ACE2) that can improve or decrease binding of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – including two variants with distinct population distributions showing an enhanced affinity for viral spike glycoprotein.

5 Jul 2021

Antibiotic clofoctol shows potential against SARS-CoV-2

In a recent study, a group of French researchers aimed to reduce the regulatory preclinical development steps that potential candidates are normally subjected to.

5 Jul 2021

Syndrome News and Research

Study explores the prevalence of long COVID in England

Real-world evidence for effectiveness of vaccination against 4 SARS-CoV-2 VOCs in Canada

Vaccinate big cats? New report shows SARS-CoV-2 Delta variant infecting endangered lions

SARS-CoV-2 Lambda variant spreading rapidly in South America, report reveals

Study shows antibody titers after natural SARS-CoV-2 infection last longer than previously thought

COVID-19 vaccination may be stemming evolution of “fitter” SARS-CoV-2 variants

Moderna’s COVID-19 vaccine elicits durable T cell memory and antibody responses

Fecal transplant and fiber supplementation can benefit patients with obesity-related metabolic syndrome

22 blood plasma lipids found to be associated with lower symptom improvement in schizophrenia

Plant compounds inhibit Mpro of SARS-CoV-2 and HCoV-229E in vitro

Deletion of an embryonic gene in liver cells completely wipes out bile ducts of newborn mice

Study provides a reliable early prognostic biomarker for COVID-19 severity

Angiotensin II type 1 receptor-targeting autoantibodies may increase COVID-19 severity

Serum testosterone status recovery an accurate predictor of survival in male COVID-19 patients

Study examines evolution and avidity of anti-SARS-CoV-2 IgG antibodies after mRNA vaccination

Study explores the effects of SARS-CoV-2 (and other betacoronaviruses) on cellular mRNA processing

COVID-19 recovered vaccinated individuals more protected from Delta variant

CRISPRa identifies potassium channels as neuronal entry factors and druggable targets for SARS-CoV-2

Study explores how human ACE2 variants can modify SARS-CoV-2 binding

Antibiotic clofoctol shows potential against SARS-CoV-2

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News